^
    Back
    Association details:
    Biomarker:TP53 wild-type
    Cancer:Lymphoma
    Drug:ALRN-6924 (MDM2 inhibitor, MDMX inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

    Excerpt:
    ...- Karnofsky performance status ≥ 50% for patients ≥16 years of age and/or Lansky ≥ 50% for patients ication, high-copy gain, or PPM1D activating mutation and WT TP53...
    Trial ID:
    NCT03654716
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

    Excerpt:
    ...- Cohort specific biomarkers, including confirmed or anticipated WT TP53 (Phase 1 and PTCL expansion cohorts) and MDM2-amplification or MDM2/CDK4-co-amplification (solid tumor expansion cohort)...
    Trial ID:
    NCT02264613
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53

    Published date:
    07/22/2021
    Excerpt:
    Two schedules were evaluated for safety, pharmacokinetics, pharmacodynamics, and anti-tumor effects in patients with solid tumors or lymphomas...In 41 efficacy-evaluable patients with TP53 wild-type disease across both schedules the disease control rate was 59%. Two patients had confirmed complete responses, two had confirmed partial responses, 20 had stable disease.
    DOI:
    10.1158/1078-0432.CCR-21-0715